Please use this identifier to cite or link to this item: 10.1007/s00431-022-04552-2
Title: Febrile children with comorbidities at the emergency department — a multicentre observational study
Authors: Borensztajn, Dorine M.
Hagedoorn, Nienke N.
Carrol, Enitan D.
von Both, Ulrich
Emonts, Marieke
van der Flier, Michiel
de Groot, Ronald
Herberg, Jethro
Kohlmaier, Benno
Levin, Michael
Lim, Emma
Maconochie, Ian K.
Martinon-Torres, Federico
Nijman, Ruud G.
Pokorn, Marko
Rivero-Calle, Irene
Tsolia, Maria
van der Velden, Fabian J.S.
Vermont, Clementien
Zavadska, Dace
Zenz, Werner
Zachariasse, Joany M.
Moll, Henriette A.
Department of Paediatrics
Keywords: Chronic disease;Comorbidity;Emergency care;Fever;Infectious diseases;3.2 Clinical medicine;1.1. Scientific article indexed in Web of Science and/or Scopus database;Pediatrics, Perinatology, and Child Health;SDG 3 - Good Health and Well-being
Issue Date: Sep-2022
Citation: Borensztajn , D M , Hagedoorn , N N , Carrol , E D , von Both , U , Emonts , M , van der Flier , M , de Groot , R , Herberg , J , Kohlmaier , B , Levin , M , Lim , E , Maconochie , I K , Martinon-Torres , F , Nijman , R G , Pokorn , M , Rivero-Calle , I , Tsolia , M , van der Velden , F J S , Vermont , C , Zavadska , D , Zenz , W , Zachariasse , J M & Moll , H A 2022 , ' Febrile children with comorbidities at the emergency department — a multicentre observational study ' , European Journal of Pediatrics , vol. 181 , no. 9 , pp. 3491-3500 . https://doi.org/10.1007/s00431-022-04552-2
Abstract: We aimed to describe characteristics and management of children with comorbidities attending European emergency departments (EDs) with fever. MOFICHE (Management and Outcome of Fever in children in Europe) is a prospective multicentre study (12 European EDs, 8 countries). Febrile children with comorbidities were compared to those without in terms of patient characteristics, markers of disease severity, management, and diagnosis. Comorbidity was defined as a chronic underlying condition that is expected to last > 1 year. We performed multivariable logistic regression analysis, displaying adjusted odds ratios (aOR), adjusting for patient characteristics. We included 38,110 patients, of whom 5906 (16%) had comorbidities. Most common comorbidities were pulmonary, neurologic, or prematurity. Patients with comorbidities more often were ill appearing (20 versus 16%, p < 0.001), had an ED-Paediatric Early Warning Score of > 15 (22 versus 12%, p < 0.001), or a C-reactive protein > 60 mg/l (aOR 1.4 (95%CI 1.3–1.6)). They more often required life-saving interventions (aOR 2.7, 95% CI 2.2–3.3), were treated with intravenous antibiotics (aOR 2.3, 95%CI 2.1–2.5), and were admitted to the ward (aOR 2.2, 95%CI 2.1–2.4) or paediatric intensive care unit (PICU) (aOR 5.5, 95% CI 3.8–7.9). They were more often diagnosed with serious bacterial infections (aOR 1.8, 95%CI 1.7–2.0), including sepsis/meningitis (aOR 4.6, 95%CI 3.2–6.7). Children most at risk for sepsis/meningitis were children with malignancy/immunodeficiency (aOR 14.5, 8.5–24.8), while children with psychomotor delay/neurological disease were most at risk for life-saving interventions (aOR 5.3, 4.1–6.9) or PICU admission (aOR 9.7, 6.1–15.5). Conclusions: Our data show how children with comorbidities are a population at risk, as they more often are diagnosed with bacterial infections and more often require PICU admission and life-saving interventions.What is Known:• While children with comorbidity constitute a large part of ED frequent flyers, they are often excluded from studies.What is New:• Children with comorbidities in general are more ill upon presentation than children without comorbidities.• Children with comorbidities form a heterogeneous group; specific subgroups have an increased risk for invasive bacterial infections, while others have an increased risk of invasive interventions such as PICU admission, regardless of the cause of the fever.
Description: Funding Information: DB, UB, EC, ME, MF, NH, BK, FMT, HM, EL, ML, MP, IRC, MT, CV, DZ, and WZ report grants from the European Union Horizon 2020 research and innovation programme during the study conduct. MP reports a grant from Pfizer and financial support from Pfizer and Sanofi outside the submitted work. MF reports a grant from CSL Behring outside the submitted work. RN reports a grant from the National Institute for Health Research during the study conduct. ME reports financial support from the National Institute for Health Research Biomedical Research Centre based at Newcastle Hospitals NHS Foundation Trust and Newcastle University during the study conduct. MT is a member of the Advisory Board of MSD and Pfizer, a member of the National Committee on Immunization Practices, and a member of the national Scientific Advisory Group for the management of the pandemic. All other authors declare no competing interests. Funding Information: This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 668303 and No. 848196. The research was supported by the National Institute for Health Research Biomedical Research Centre based at Imperial College (JH, ML) and at Newcastle Hospitals NHS Foundation Trust and Newcastle University (EL, ME), grant number not applicable. Publisher Copyright: © 2022, The Author(s).
DOI: 10.1007/s00431-022-04552-2
ISSN: 0340-6199
Appears in Collections:Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure

Files in This Item:


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.